BioLargo and Garratt-Callahan Team Up for Product Development Project
Tuesday, February 2, 2021 9:15 AM
WESTMINSTER, CA / ACCESSWIRE / February 2, 2021 / BioLargo, Inc. (OTCQB:BLGO), developer of cutting-edge environmental technologies and a full-service engineering firm, announced that it has teamed up with Garratt-Callahan Company, a national industrial water treatment company, to co-create and develop a wastewater treatment product that will salvage usable water from commercial facilities wastewater streams.
Their mutual concern for the environment and the care and conservation of water make the collaboration between BioLargo and Garratt-Callahan a symbiotic match. BioLargo's mission to provide unique disruptive solutions to deliver clean air, clean water and a clean, safe environment combined with Garratt-Callahan's 116 years of experience and commitment to provide safer water treatment and deliver unrivaled customer service make for a formidable combination.
The shared goal is to design and manufacture a new piece of wastewater treatment equipment centered around a new patented water treatment process developed by Garratt-Callahan to reduce wastewater discharged from commercial facilities. BioLargo's engineering division (BioLargo Engineering, Science & Technologies) will design, build and pilot a prototype of the new system. When refined, the two organizations have agreed to offer the system commercially to Garratt-Callahan customers and select BioLargo distributors, with BioLargo serving as the equipment's ongoing manufacturer. The collaborative team targets having full-scale units in operation in mid to late 2021 or early 2022. Both companies expect strong demand for this product offering among their wastewater treatment customers.
Garratt-Callahan has signed a purchase order with BioLargo to permit work to begin. The two organizations believe this will be the first collaboration of many. Discussions are underway between leaders at both companies regarding the future utilization of BioLargo's other technology assets to serve their customers' needs.
President and CEO of BioLargo Dennis P. Calvert commented, "This is a tremendous opportunity for BioLargo and Garratt-Callahan to work together to address customers' pressing wastewater treatment needs. Garratt-Callahan has a great reputation and history as a reliable and innovative water treatment services company, and they recognized BioLargo as a reliable innovator in the water treatment technology space. This collaboration is a perfect fit with shared corporate values of fairness, honesty, and integrity. We believe we will help solve important water treatment challenges that Garratt-Callahan's customers face. We look forward to sharing more information as the project progresses."
Garratt-Callahan is an Industrial Water Treatment Company. Founded in 1904, G-C has been providing water treatment products and services and manufacture a complete line of water treatment products to control scale, corrosion, and sludge buildup on heat transfer surfaces in steam and hot water boilers and cooling systems.
Safe Harbor Act
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include without limitation those about BioLargo's (the "Company") expectations regarding the impact of the COVID-19 pandemic; anticipated revenue; and plans for future operations. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Risks and uncertainties include without limitation: the effect of the COVID-19 pandemic on the Company's business, results of operations, financial condition, and stock price; the effect of regional economic conditions on the Company's business, including effects on purchasing decisions by consumers and businesses; the ability of the Company to compete in markets that are highly competitive and subject to rapid technological change; the ability of the Company to manage frequent introductions and transitions of products and services, including delivering to the marketplace, and stimulating customer demand for, new products, services, and technological innovations on a timely basis; the dependency of the Company on the performance of distributors of the Company's products. More information on these risks and other potential factors that could affect the Company's business and financial results is included in the Company's filings with the SEC, including in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of the Company's most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings. The Company assumes no obligation to update any forward-looking statements or information, which speak as of their respective dates.
SOURCE: BioLargo, Inc.
